The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer

Loh, Yan Ni; Hedditch, Ellen L.; Baker, Laura A.; Jary, Eve; Ward, Robyn L.; Ford, Caroline

doi:10.1186/1471-2407-13-174

Cited by 108 publications

(85 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Enhanced expression of plasticity networks (4,15,16), as well as mediators of EMT (17,18), in the primary tumor has been associated with treatment failure. Information about changes that occur with tumor progression on treatment, however, is not readily available.…”

Section: Discussionmentioning

confidence: 99%

Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy

McBryan

Fagan

McCartan

et al. 2015

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Disease recurrence is a common problem in breast cancer and yet the mechanisms enabling tumor cells to evade therapy and colonize distant organs remain unclear. We sought to characterize global expression changes occurring with metastatic disease progression in the endocrine-resistant setting.Experimental Design: Here, for the first time, RNAsequencing has been performed on matched primary, nodal, and liver metastatic tumors from tamoxifen-treated patients following disease progression. Expression of genes commonly elevated in the metastases of sequenced patients was subsequently examined in an extended matched patient cohort with metastatic disease from multiple sites. The impact of tamoxifen treatment on endocrineresistant tumors in vivo was investigated in a xenograft model.Results: The extent of patient heterogeneity at the gene level was striking. Less than 3% of the genes differentially expressed between sequential tumors were common to all patients. Larger divergence was observed between primary and liver tumors than between primary and nodal tumors, reflecting both the latency to disease progression and the genetic impact of intervening therapy. Furthermore, an endocrine-resistant in vivo mouse model demonstrated that tamoxifen treatment has the potential to drive disease progression and establish distant metastatic disease. Common functional pathways altered during metastatic, endocrine-resistant progression included extracellular matrix receptor interactions and focal adhesions.Conclusions: This novel global analysis highlights the influence of primary tumor biology in determining the transcriptomic profile of metastatic tumors, as well as the need for adaptations in cellcell communications to facilitate successful tumor cell colonization of distant host organs.

show abstract

Section: Discussionmentioning

confidence: 99%

Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy

McBryan

Fagan

McCartan

et al. 2015

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…EGCG induces the disruption of adherent junction formation and the accumulation of extra-nuclear β-catenin in MCF-7 cells (19,20). The β-catenin signaling pathway is involved in EGCG-mediated anticancer protection (21). Therefore, members of the β-catenin pathway in tissues of breast cancer patients are potential targets of EGCG.…”

Section: Epigallocatechin Gallate Inhibits the Growth Of Mda-mb-231 Bmentioning

confidence: 99%

Epigallocatechin gallate inhibits the growth of MDA-MB-231 breast cancer cells via inactivation of the β-catenin signaling pathway

et al. 2017

View full text Add to dashboard Cite

Abstract. Epigallocatechin gallate (EGCG), a major constituent of green tea, has potential as a treatment for a variety of diseases, including cancer. EGCG induces apoptosis and inhibits tumorigenesis through multiple signaling pathways in breast cancer cells. β-catenin signaling modulators could be useful in the prevention and therapy of breast cancer. However, the precise anticancer effect of EGCG through the β-catenin signaling pathway in breast cancer is unclear. The present study investigated the association between β-catenin expression and clinicopathological factors of breast cancer patients, and the effect of EGCG on β-catenin expression in breast cancer cells. β-catenin expression was analyzed according to the clinicopathological factors of 74 patients with breast cancer. All patients were females diagnosed with invasive ductal carcinoma. Western blot analysis revealed that β-catenin was expressed at higher levels in breast cancer tissue than in normal tissue. β-catenin expression was associated with lymph node metastasis (P=0.04), tumor-node-metastasis stage (P=0.03) and estrogen receptor status (P<0.01). EGCG decreased MDA-MB-231 cell viability and significantly downregulated the expression of β-catenin, phosphorylated Akt and cyclin D1. Remarkably, additive effects of LY294002 and wortmannin, two phosphatidylinositol-3 kinase inhibitors, were observed. The present results suggest that EGCG inhibits the growth of MDA-MB-231 cells through the inactivation of the β-catenin signaling pathway. Based on these promising results, EGCG may be a potential treatment for triple negative breast cancer patients.

show abstract

“…Wnt signaling pathway is an important developmental pathway that is frequently dysregulated in human cancers including breast cancer (157)(158)(159)(160). Wnt signaling is important for cell migration, invasion, adhesion and survival.…”

Section: Signaling Pathways That Regulate Emt In Tumor Microenvironmentmentioning

confidence: 99%

Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (Review)

et al. 2014

View full text Add to dashboard Cite

Abstract. Anti-estrogens such as tamoxifen are widely used in the clinic to treat estrogen receptor-positive breast tumors. Patients with estrogen receptor-positive breast cancer initially respond to treatment with anti-hormonal agents such as tamoxifen, but remissions are often followed by the acquisition of resistance and, ultimately, disease relapse. The development of a rationale for the effective treatment of tamoxifen-resistant breast cancer requires an understanding of the complex signal transduction mechanisms. In the present study, we explored some mechanisms associated with resistance to tamoxifen, such as pharmacologic mechanisms, loss or modification in estrogen receptor expression, alterations in co-regulatory proteins and the regulation of the different signaling pathways that participate in different cellular processes such as survival, proliferation, stress, cell cycle, inhibition of apoptosis regulated by the Bcl-2 family, autophagy, altered expression of microRNA, and signaling pathways that regulate the epithelial-mesenchymal transition in the tumor microenvironment. Delineation of the molecular mechanisms underlying the development of resistance may aid in the development of treatment strategies to enhance response and compromise resistance.

show abstract

The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer

Cited by 108 publications

References 45 publications

Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy

Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy

Epigallocatechin gallate inhibits the growth of MDA-MB-231 breast cancer cells via inactivation of the β-catenin signaling pathway

Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer (Review)

Contact Info

Product

Resources

About